Sanofi (SNY)
NASDAQ: SNY
· Real-Time Price · USD
54.54
-0.90 (-1.62%)
At close: May 05, 2025, 3:59 PM
54.59
0.09%
After-hours: May 05, 2025, 04:05 PM EDT
-1.62% (1D)
| Bid | 54 |
| Market Cap | 133.2B |
| Revenue (ttm) | 43.77B |
| Net Income (ttm) | 6.3B |
| EPS (ttm) | 2.83 |
| PE Ratio (ttm) | 19.27 |
| Forward PE | 10.58 |
| Analyst | Buy |
| Ask | 55.6 |
| Volume | 1,615,597 |
| Avg. Volume (20D) | 2,928,196.1 |
| Open | 55.28 |
| Previous Close | 55.44 |
| Day's Range | 54.14 - 55.50 |
| 52-Week Range | 45.80 - 60.12 |
| Beta | 0.48 |
About SNY
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseas...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jul 1, 2002
Employees 82,878
Stock Exchange NASDAQ
Ticker Symbol SNY
Website https://www.sanofi.com
Analyst Forecast
According to 2 analyst ratings, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $62.5, which is an increase of 14.59% from the latest price.
Stock Forecasts3 months ago
+3.84%
Sanofi shares are trading higher after the company...
Unlock content with
Pro Subscription
4 months ago
+6.65%
Sanofi shares are trading higher after the company and Teva announced that primary endpoints were met in the Phase 2b trial of Duvakitug for ulcerative colitis and Crohn's disease.
